Child Immunization Schedule Addendum

Recommendations for Ages 18 Years or Younger, United States, 2025

Purpose

Outline new or updated vaccine recommendations that have occurred since October 24, 2024.

How to use the schedule

To make vaccination recommendations, healthcare providers should:

  1. Determine recommended vaccine by age (Table 1 – By Age)
  2. Determine recommended interval for catch-up vaccination (Table 2 – Catch-up)
  3. Assess need for additional recommended vaccines by medical condition or other indication (Table 3 – By Medical Indication)
  4. Review vaccine types, frequencies, intervals, and considerations for special situations (Notes)
  5. Review contraindications and precautions for vaccine types (Appendix)
  6. Review new or updated ACIP guidance (Addendum)

Addendum

In addition to the recommendations presented in the previous sections of this immunization schedule, CDC has approved the following ACIP recommendations since October 24, 2024.

Vaccines Recommendations Effective Date of Recommendation
Meningococcal (MenACWY-CRM/MenB-4C, Penmenvy) ACIP recommends GSK's MenABCWY vaccine may be used when both MenACWY and MenB are indicated at the same visit*
*(1) healthy persons aged 16–23 years (routine schedule) when shared clinical decision-making favors administration of MenB vaccine and (2) persons aged ≥10 years who are at increased risk for meningococcal disease (e.g., because of persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia).
June 25, 2025
Note: As of May 29, 2025, the schedule incorporates the HHS directive regarding COVID-19 vaccine recommendations. (Changes were made to tables and notes for COVID-19 vaccines in pregnant women and children/adolescents ages 6 months through 17 years who are not moderately or severely immunocompromised.)
The effective date is the date when the recommendation was adopted and became official.